My Ultimate Sign-in System Made Me Invincible Chapter 496 Volunteer Selection Criteria Speculations

Over ten days had elapsed since Nova Technologies broadcast their update on LucidNet, notifying the world that the commencement date for the off-world clinical trials had been expedited.

They had pledged to reveal the volunteer selection process within twelve days, yet the platform remained devoid of such news.

This silence was hardly shocking at this juncture. Nova Technologies strictly adhered to their own internal clock, a fact they had highlighted on numerous occasions. Nevertheless, the anticipation generated a unique form of tension; it lacked the explosive outrage seen immediately after the initial nanite disclosure, settling instead into a more subdued, fixated state. The populace remained vigilant, monitoring for developments and filling the void with endless theories.

The ideological clash between advocates and detractors had dampened slightly. While nothing had been truly settled, the fervor had shifted from a deafening roar to a consistent hum. Both factions had largely exhausted their primary arguments, opting to consolidate their positions rather than pursue further debate.

A brief initiative to steer the discourse toward contrasting Nova Technologies with traditional pharmaceutical giants disintegrated almost immediately. Both sides turned on the instigator of that thread with unusual harmony, and the post was scrubbed shortly thereafter.

It was one of those rare instances where both camps found common ground: such a comparison benefited neither side and merely muddied waters that were already sufficiently opaque.

What emerged in its place was far more concentrated. Public interest pivoted toward the volunteer selection criteria, and the speculation regarding that topic was reaching a fever pitch.

The obvious, baseline assumptions were exhausted in short order. Terminal diagnoses. Untreatable conditions. Congenital genetic disorders. Spinal trauma. Amputations. These surfaced in every discussion thread as foundational givens—afflictions so severe and clearly beyond contemporary medical expertise that almost no one contested them as primary candidates.

However, the obvious scenarios quickly dwindled, and it was there that the substantive debates commenced.

***

One user authored a thread that rapidly gained momentum: "Here is what I believe everyone is overlooking regarding the selection criteria: Nova Technologies is not merely conducting a clinical trial. They are executing a grand demonstration. The conditions they select will be curated both for their medical magnitude and their persuasive potential. They require outcomes that are impossible to negate, impossible to write off as a placebo effect, and impossible to replicate via standard procedures. Consequently, they will prioritize conditions where the success is visually and statistically irrefutable."

The post continued: "Consider total spinal cord injuries. Not partial impairment, but complete severance. The sort of case where every major medical institution globally concedes there is no path to recovery. If a patient with a total spinal cord injury stands up and leaves the Lunar Base Sanctuary, no counter-argument exists. No disputing methodology. No claiming that they perhaps would have recovered anyway. The results dictate the narrative and cannot be explained away."

The responses were largely constructive rather than combative.

One user countered: "That reasoning holds weight, but it introduces a troubling dilemma. Should participant selection focus on dramatic visual impact, then those suffering from less obviously visible ailments—such as chronic pain or autoimmune disorders—might be sidelined, despite their agony being equally profound. A successful nanite intervention for lupus is medically monumental, yet it lacks the unmistakable visual proof of somebody taking steps for the first time in two decades."

Another commentator replied: "That is a valid worry, but I suspect you are viewing this through an incorrect lens. Nova Technologies is not a pharmaceutical firm seeking FDA clearance for a singular drug. They are showcasing a versatile platform. The nanites canoretically rectify any biological dysfunction. Therefore, they are not strictly looking for conditions where nanites are effective; they are seeking conditions that best showcase the versatility of the entire platform. Breadth of capability matters just as much as visual impact."

A different thread explored a completely separate angle.

"Everyone assumes the selection process will be strictly medical," one user argued. "However, Nova Technologies maintains a regional perspective. Every action they have taken has been calculated—the price tiers, the observer protocols, the accelerated timeline. None of that was coincidental. Why would the choice of volunteers be any different? If a significant portion of volunteers hail from regions where these conditions are endemic, the demonstration transforms into something entirely different. It ceases to be just a medical trial and becomes proof that the technology was crafted for everyone, not merely those who already possess medical alternatives."

The thread expanded on the argument: "If they recruit volunteers exclusively from affluent nations with robust healthcare infrastructures, the narrative is predictable—they are assisting those who already have options. But if a notable percentage of volunteers come from areas where the conditions being treated are rampant and existing healthcare is incapable of addressing them, the demonstration takes on a new essence. It signifies a commitment to global accessibility, rather than just raw medical power."

A challenger retorted: "That introduces a variable unrelated to medicine. You are implying they weigh national origin as a selection metric, which raises significant questions regarding the ethics of such a practice. Medical selection must be dictated by physical necessity, not by where someone was born or the narrative their recovery provides."

Another responded: "But medical necessity and the geographic clustering of that necessity are intrinsically linked. Certain disorders are far more frequent in specific locales due to environmental factors, genetic prevalence, or gaps in healthcare access. If Nova Technologies prioritizes conditions where current medical options are deficient or non-existent, geographic diversity in the volunteer pool will occur organically. This is not political theater; it is a clinical reflection of where the most desperate medical needs truly lie."

A thread that drew sustained engagement originated from a user who approached the challenge from an entirely fresh perspective.

"I haven't seen anyone discuss age as a key selection variable, yet I consider it one of the most vital. The nanites appear capable of correcting genetic anomalies. Consequently, the timing of when those anomalies are rectified becomes medically intriguing. A genetic condition corrected at forty, following decades of secondary biological degradation, yields different data than the same condition corrected at age eight, before those effects could compound. Both are valuable, but the data produced is distinct."

The thread continued: "This makes pediatric cases uniquely significant in a way adult cases are not. It also renders them ethically complex in a way that adult cases are not. Minors cannot provide informed consent. Guardians grant consent on their behalf. The stakes of an experimental trial, even one with a high confidence in safety, shift fundamentally when the subject is a child."

A user with a claimed medical background offered a rebuttal: "This is one of the more profound points in this discussion. Pediatric inclusion in clinical trials is governed by a distinct regulatory and ethical framework specifically because the consent hurdle is real and immense. While Nova Technologies may operate outside those specific frameworks due to their off-world jurisdiction, it does not mean they will eschew equivalent standards. A company that has gone to such lengths to ensure observer access and transparency is not going to casually bypass pediatric consent procedures."

Another added: "It is also worth noting that pediatric genetic disorders represent some of the most emotionally undeniable demonstration cases. A child born with a condition that is corrected in a month, followed by normal development—that is a narrative no one can argue against. Medically, ethically, and emotionally, it hits home completely."

The debates raged on, and every participant presented a valid viewpoint.

However, emerging from that thread came a quieter, widely shared post from a user who steered clear of speculating on criteria altogether.

"I have been suffering from ALS for three years. I am not posting this to solicit sympathy. I am posting because I have been observing this conversation, and I want to share a word with others in my situation who might be reading. We are unaware of what the criteria will be. We are unaware of when the announcement will arrive. We are unaware if conditions like mine will be part of this phase or a subsequent one. But something is happening. That truth persists, regardless of everything else. Whatever Nova Technologies might be, whatever your stance on their business model, their silence, or their pricing—something is genuinely taking place. For the first time in three years, I feel a sense of uncertainty about what the coming year holds. That uncertainty is not nothing."

The post amassed hundreds of thousands of upvotes within hours. The feedback was largely subdued—users responded with a level of restraint born from the recognition that the moment did not require additional clamor.

A few hours later, a single reply was left under that post: "The announcement is live. Go read it."